在体外纤维溶解治疗后,血小板依赖的血栓生成
D L Aronson1, P Chang, C M Kessler
1George Washington University Medical Center, Washington, D.C. 20037.
Circulation
|May 1, 1992
概括
像rt-PA这样的纤维溶解剂可以直接激活血小板,增加血栓生成,并可能导致转血栓形成. 这表明直接的血小板效应独立于等离子素激活.
科学领域:
- 生物化学 生物化学
- 血液学 血液学 血液学
- 心血管研究研究心血管研究
背景情况:
- 纤维溶解药物治疗对于治疗血栓形成至关重要,但与转血栓形成有关.
- 有证据表明,增加的凝血和血小板激活都有助于这种现象.
研究的目的:
- 调查纤维解质剂对血小板激活和血栓生成的直接影响.
- 为了确定纤维溶解剂是否可以直接影响血小板功能,独立于等离子体.
主要方法:
- 富于血小板的血 (PRP) 和洗净的血小板用尿激酶,复合组织类型等离子素激活剂 (rt-PA) 或等离子素进行化.
- 血栓生成和凝血时间测量在受治疗和未治疗的PRP和血中.
- 用纤维溶解剂治疗的洗净的血小板被添加到血小板贫乏的血中,以评估它们对血栓生成的支持.
主要成果:
- 纤维溶解剂加速了PRP中的血栓生成,并减少了凝固时间.
- 重组组织类型等离子体激活剂 (rt-PA) 和等离子体,但不是尿激酶,增强了洗净的血小板支持血栓生成的能力.
- 即使没有等离子体生成,也观察到rt-PA对血小板的促凝效应.
结论:
- 等离子素直接增加了血小板对前激活的支持.
- 重组组织类型等离子体激活剂 (rt-PA) 可以直接影响血小板,增强独立于等离子体的血栓生成.
- 这些发现突出了由纤维溶解剂直接激活血小板的机制,这可能解释治疗后的转血栓形成.
更多相关视频
09:19In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
05:49Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Published on: November 29, 2024
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Structure and Function of Platelets
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:09Coagulation
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.